Intrathecal Pemetrexed for Leptomeningeal Metastasis

Status Active, not recruiting

Clinical Trial Summary

Intrathecal chemotherapy is one of the most important treatment modalities for leptomeningeal metastasis of solid tumors. In the previous study(Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastasis From Non-small Cell Lung Cancer: A Prospective Pilot Clinical Trial. ClinicalTrials.gov identification number: NCT03101579), pemetrexed presented feasibility of intrathecal administration. Pemetrexed at 10 mg dose level on the schedule of 1-2 times per week was recommended as an intrathecal administration agent for patients with refractory leptomeningeal metastases from non-small-cell lung cancer in the previous study. Moreover, the maximum-tolerated dose and recommended dose of intrathecal pemetrexed in the previous study was obtained without vitamin supplementation. Vitamin supplementation has been shown to reduce pemetrexed-induced myelosuppression. In this study, the regimen of intrathecal pemetrexed with folic acid and vitamin B12 supplementation may provide higher safety. Therefore, the purpose of this study is to investigate the maximally tolerated dose and evaluate the safety and effectiveness of intrathecal pemetrexed with vitamin supplementation as the first-line intrathecal chemotherapy in patients with leptomeningeal metastases from malignant solid tumors.

Clinical Trial Description

This is a phase I/II clinical trial. The objective of the study is patients with leptomeningeal metastases from solid tumors. Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 4 weeks. In phase I study, the initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg.... A minimum of three patients and a maximum of six are enrolled in each cohort. A dose-limiting toxicity is defined as grade 3 neurological toxicities (e.g., chemical meningitis) or other grade 4 toxicity. If none of the three patients experiences any dose-limiting toxicity, the subsequent three patients are enrolled at the next higher dosage level. If one of three patients experiences a dose-limiting toxicity, up to three more patients are enrolled at the same level. The maximum-tolerated dose is defined as the dose where 0/3 or 1/6 patients experiences a dose-limiting toxicity with at least two patients encountering dose-limiting toxicity at the higher dose. If more than two patients experience a dose-limiting toxicity, that level is considered too toxic. The maximum-tolerated dose is exceeded and an additional three patients should be treated at the next lower dose level. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks. In phase II study, the maximum-tolerated dose determined in phase I study is chosen. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05289908
Study type	Interventional
Source	The First Hospital of Jilin University
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	February 21, 2022
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01438021` - Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease	N/A
Completed	`NCT02616393` - Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases	Phase 2
Completed	`NCT03101579` - Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer	Phase 1
Active, not recruiting	`NCT03719768` - Avelumab With Radiotherapy in Patients With Leptomeningeal Disease	Phase 1
Terminated	`NCT00005812` - Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma	Phase 2
Terminated	`NCT03661424` - BATs in Patients With Breast Cancer and Leptomeningeal Metastases	Phase 1
Recruiting	`NCT05184816` - A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis	Phase 1
Not yet recruiting	`NCT03613181` - ANG1005 in Leptomeningeal Disease From Breast Cancer	Phase 3
Terminated	`NCT03275402` - 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases	Phase 2/Phase 3
Completed	`NCT01645839` - Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer	Phase 3
Completed	`NCT03520504` - Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases	Phase 1
Completed	`NCT00992602` - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer	Phase 2
Completed	`NCT00005811` - Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment	Phase 2
Active, not recruiting	`NCT04343573` - Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.